NeuraLight Wins Fast Company’s World Changing Ideas Award for Its Innovation in Brain Function Measurement
NeuraLight's precision brain function platform earns the company a spot on the magazine’s prestigious list for its impact on the future of healthcare
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, a leader in precision brain function biomarkers, has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, honored in the Future of Health category for companies reshaping how the world measures, treats, and manages disease. Fast Company's awards are among the most competitive in the field, drawing more than 1,500 entries this year.
NeuraLight’s win comes as brain health enters a new era. As the field shifts from managing disease to protecting and restoring brain function, one bottleneck persists: the ability to measure it precisely and track how it changes over time. By leveraging eye movements as a precise output channel for probing specific brain functions, and harnessing the power of AI, NeuraLight delivers precision biomarkers for drug development and brain health programs, opening new possibilities for patient care.
Previous Fast Company innovation winners include category-defining companies like WHOOP, which redefined performance tracking through wearables, and Dexcom, which transformed diabetes management through continuous glucose monitoring. Both companies did more than just introduce new technologies, they redefined how health is measured.
NeuraLight is aiming to have that same kind of impact on brain health. The recognition follows a series of clinical and commercial milestones. NeuraLight-led clinical trials have demonstrated the superior sensitivity of its measures, while partner-led trials have shown that the NeuraLight measurement layer can strengthen clinical programs and contribute to their success. Among the most notable is the company's expansion to power GLP-1 therapeutics programs, underscored by its strategic partnership with a pharma company developing GLP-1s designed for neuroprotection.
These developments follow the addition of world-renowned neurologists and scientists to the company's leadership, including Nobel laureate Thomas Südhof, MD, who joined as Scientific Co-Founder.
“We’re humbled to be recognized by Fast Company. Brain health is moving from an era of observation to one of intervention, and the ability to measure brain function precisely and at scale is foundational to that shift – across drug development, health and performance and patient care. That is the mission driving everything we do at NeuraLight.” — Edmund Ben Ami, Co-Founder and CEO of NeuraLight